A widely used retinoic acid receptor antagonist induces peroxisome proliferator-activated receptor-γ activity

Michael Schupp, Joshua C. Curtin, Roy J. Kim, Andrew N. Billin, Mitchell A. Lazar

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Nuclear receptors (NRs) are transcription factors whose activity is regulated by the binding of small lipophilic ligands, including hormones, vitamins, and metabolites. Pharmacological NR ligands serve as important therapeutic agents; for example, all-trans retinoic acid, an activating ligand for retinoic acid receptor α (RARα), is used to treat leukemia. Another RARα ligand, (E)-S,S-dioxide-4-(2-(7-(heptyloxy)-3,4-dihydro-4,4- dimethyl-2H-1-benzothiopyran-6-yl)-1-propenyl)-benzoic acid (Ro 41-5253), is a potent antagonist that has been a useful and purportedly specific probe of RARα function. Here, we report that Ro 41-5253 also activates the peroxisome proliferatoractivated receptor γ (PPARγ), a master regulator of adipocyte differentiation and target of widely prescribed antidiabetic thiazolidinediones (TZDs). Ro 41-5253 enhanced differentiation of mouse and human preadipocytes and activated PPARγ target genes in mature adipocytes. Like the TZDs, Ro 41-5253 also down-regulated PPARγ protein expression in adipocytes. In addition, Ro 41-5253 activated the PPARγ-ligand binding domain in transiently transfected HEK293T cells. These effects were not prevented by a potent RARα agonist or by depleting cells of RARα, indicating that PPARγ activation was not related to RARα antagonism. Indeed, Ro 41-5253 was able to compete with TZD ligands for binding to PPARγ, suggesting that Ro 41-5253 directly affects PPAR activity. These results vividly demonstrate that pharmacological NR ligands may have "off-target" effects on other NRs. Ro 41-5253 is a PPARγ agonist as well as an RARα antagonist whose pleiotropic effects on NRs may signify a unique spectrum of biological responses.

Original languageEnglish (US)
Pages (from-to)1251-1257
Number of pages7
JournalMolecular Pharmacology
Volume71
Issue number5
DOIs
StatePublished - May 2007

Fingerprint

Retinoic Acid Receptors
Peroxisome Proliferator-Activated Receptors
Peroxisomes
Cytoplasmic and Nuclear Receptors
Ligands
Thiazolidinediones
Adipocytes
Pharmacology
Benzoic Acid
Ro 41-5253
Tretinoin
Hypoglycemic Agents
Vitamins
Leukemia
Transcription Factors
Hormones

ASJC Scopus subject areas

  • Pharmacology

Cite this

A widely used retinoic acid receptor antagonist induces peroxisome proliferator-activated receptor-γ activity. / Schupp, Michael; Curtin, Joshua C.; Kim, Roy J.; Billin, Andrew N.; Lazar, Mitchell A.

In: Molecular Pharmacology, Vol. 71, No. 5, 05.2007, p. 1251-1257.

Research output: Contribution to journalArticle

Schupp, Michael ; Curtin, Joshua C. ; Kim, Roy J. ; Billin, Andrew N. ; Lazar, Mitchell A. / A widely used retinoic acid receptor antagonist induces peroxisome proliferator-activated receptor-γ activity. In: Molecular Pharmacology. 2007 ; Vol. 71, No. 5. pp. 1251-1257.
@article{9574ef8be5084bb297bbb35383a6950d,
title = "A widely used retinoic acid receptor antagonist induces peroxisome proliferator-activated receptor-γ activity",
abstract = "Nuclear receptors (NRs) are transcription factors whose activity is regulated by the binding of small lipophilic ligands, including hormones, vitamins, and metabolites. Pharmacological NR ligands serve as important therapeutic agents; for example, all-trans retinoic acid, an activating ligand for retinoic acid receptor α (RARα), is used to treat leukemia. Another RARα ligand, (E)-S,S-dioxide-4-(2-(7-(heptyloxy)-3,4-dihydro-4,4- dimethyl-2H-1-benzothiopyran-6-yl)-1-propenyl)-benzoic acid (Ro 41-5253), is a potent antagonist that has been a useful and purportedly specific probe of RARα function. Here, we report that Ro 41-5253 also activates the peroxisome proliferatoractivated receptor γ (PPARγ), a master regulator of adipocyte differentiation and target of widely prescribed antidiabetic thiazolidinediones (TZDs). Ro 41-5253 enhanced differentiation of mouse and human preadipocytes and activated PPARγ target genes in mature adipocytes. Like the TZDs, Ro 41-5253 also down-regulated PPARγ protein expression in adipocytes. In addition, Ro 41-5253 activated the PPARγ-ligand binding domain in transiently transfected HEK293T cells. These effects were not prevented by a potent RARα agonist or by depleting cells of RARα, indicating that PPARγ activation was not related to RARα antagonism. Indeed, Ro 41-5253 was able to compete with TZD ligands for binding to PPARγ, suggesting that Ro 41-5253 directly affects PPAR activity. These results vividly demonstrate that pharmacological NR ligands may have {"}off-target{"} effects on other NRs. Ro 41-5253 is a PPARγ agonist as well as an RARα antagonist whose pleiotropic effects on NRs may signify a unique spectrum of biological responses.",
author = "Michael Schupp and Curtin, {Joshua C.} and Kim, {Roy J.} and Billin, {Andrew N.} and Lazar, {Mitchell A.}",
year = "2007",
month = "5",
doi = "10.1124/mol.106.033662",
language = "English (US)",
volume = "71",
pages = "1251--1257",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "5",

}

TY - JOUR

T1 - A widely used retinoic acid receptor antagonist induces peroxisome proliferator-activated receptor-γ activity

AU - Schupp, Michael

AU - Curtin, Joshua C.

AU - Kim, Roy J.

AU - Billin, Andrew N.

AU - Lazar, Mitchell A.

PY - 2007/5

Y1 - 2007/5

N2 - Nuclear receptors (NRs) are transcription factors whose activity is regulated by the binding of small lipophilic ligands, including hormones, vitamins, and metabolites. Pharmacological NR ligands serve as important therapeutic agents; for example, all-trans retinoic acid, an activating ligand for retinoic acid receptor α (RARα), is used to treat leukemia. Another RARα ligand, (E)-S,S-dioxide-4-(2-(7-(heptyloxy)-3,4-dihydro-4,4- dimethyl-2H-1-benzothiopyran-6-yl)-1-propenyl)-benzoic acid (Ro 41-5253), is a potent antagonist that has been a useful and purportedly specific probe of RARα function. Here, we report that Ro 41-5253 also activates the peroxisome proliferatoractivated receptor γ (PPARγ), a master regulator of adipocyte differentiation and target of widely prescribed antidiabetic thiazolidinediones (TZDs). Ro 41-5253 enhanced differentiation of mouse and human preadipocytes and activated PPARγ target genes in mature adipocytes. Like the TZDs, Ro 41-5253 also down-regulated PPARγ protein expression in adipocytes. In addition, Ro 41-5253 activated the PPARγ-ligand binding domain in transiently transfected HEK293T cells. These effects were not prevented by a potent RARα agonist or by depleting cells of RARα, indicating that PPARγ activation was not related to RARα antagonism. Indeed, Ro 41-5253 was able to compete with TZD ligands for binding to PPARγ, suggesting that Ro 41-5253 directly affects PPAR activity. These results vividly demonstrate that pharmacological NR ligands may have "off-target" effects on other NRs. Ro 41-5253 is a PPARγ agonist as well as an RARα antagonist whose pleiotropic effects on NRs may signify a unique spectrum of biological responses.

AB - Nuclear receptors (NRs) are transcription factors whose activity is regulated by the binding of small lipophilic ligands, including hormones, vitamins, and metabolites. Pharmacological NR ligands serve as important therapeutic agents; for example, all-trans retinoic acid, an activating ligand for retinoic acid receptor α (RARα), is used to treat leukemia. Another RARα ligand, (E)-S,S-dioxide-4-(2-(7-(heptyloxy)-3,4-dihydro-4,4- dimethyl-2H-1-benzothiopyran-6-yl)-1-propenyl)-benzoic acid (Ro 41-5253), is a potent antagonist that has been a useful and purportedly specific probe of RARα function. Here, we report that Ro 41-5253 also activates the peroxisome proliferatoractivated receptor γ (PPARγ), a master regulator of adipocyte differentiation and target of widely prescribed antidiabetic thiazolidinediones (TZDs). Ro 41-5253 enhanced differentiation of mouse and human preadipocytes and activated PPARγ target genes in mature adipocytes. Like the TZDs, Ro 41-5253 also down-regulated PPARγ protein expression in adipocytes. In addition, Ro 41-5253 activated the PPARγ-ligand binding domain in transiently transfected HEK293T cells. These effects were not prevented by a potent RARα agonist or by depleting cells of RARα, indicating that PPARγ activation was not related to RARα antagonism. Indeed, Ro 41-5253 was able to compete with TZD ligands for binding to PPARγ, suggesting that Ro 41-5253 directly affects PPAR activity. These results vividly demonstrate that pharmacological NR ligands may have "off-target" effects on other NRs. Ro 41-5253 is a PPARγ agonist as well as an RARα antagonist whose pleiotropic effects on NRs may signify a unique spectrum of biological responses.

UR - http://www.scopus.com/inward/record.url?scp=34247546618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247546618&partnerID=8YFLogxK

U2 - 10.1124/mol.106.033662

DO - 10.1124/mol.106.033662

M3 - Article

C2 - 17290005

AN - SCOPUS:34247546618

VL - 71

SP - 1251

EP - 1257

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 5

ER -